Post-Operative Complications and Management in CRS-HIPEC

Major Complications to Monitor

Grade 3 or greater adverse events occur in 15-24% of patients, with the highest risk period extending to 60 days post-operatively 1, 2, 3
The PRODIGE 7 trial demonstrated that grade 3+ adverse events at 60 days were significantly more common (RR 1.69, 95% CI 1.03-2.77) when HIPEC was added to CRS 1, 2, 3
Treatment-related mortality ranges from 0.9-5.8% in contemporary series, with historical studies reporting up to 8% mortality 1, 3
Mortality risk is directly related to the extent of disease and completeness of cytoreduction achieved 1, 3
Monitor for creatinine elevation, which occurs in approximately 15% of patients receiving HIPEC versus 4% without HIPEC 4, 5
Anemia occurs in approximately 67% of patients with HIPEC versus 50% without 4, 5
Neutropenia and thrombocytopenia are expected complications from systemic chemotherapy toxicity 5

Only 15% of patients with isolated colorectal peritoneal metastases remain progression-free at 5 years, emphasizing the need for realistic expectations and close surveillance 1, 2, 6, 7

CRS-HIPEC should only be performed at specialized centers with substantial clinical experience, as the PRODIGE 7 trial achieved 91% complete macroscopic cytoreduction rates due to center expertise 1, 2, 6, 7
Multidisciplinary team management including medical oncology, surgical oncology, radiology, and pathology is mandatory 1, 2, 6

Delayed recognition of complications can occur, with the 60-day window for grade 3+ adverse events requiring extended vigilance beyond the typical 30-day post-operative period 1, 2, 3
Incomplete cytoreduction (residual disease >1mm) dramatically worsens outcomes; the completeness of cytoreduction is the most important prognostic factor 1, 2, 7